Artículos por temáticas

Clinical study of combined mirror and extracorporeal shock wave therapy on upper limb spasticity in poststroke patients.

Guo J, Qian S, Wang Y, Xu A.

Int J Rehabil Res. 2018 Sep 11. doi: 10.1097/MRR.0000000000000316. [Epub ahead of print]

Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment.

Baricich A, Picelli A, Santamato A, Carda S, de Sire A, Smania N, Cisari C, Invernizzi M.

Clin Drug Investig. 2018 Sep 12. doi: 10.1007/s40261-018-0701-x. [Epub ahead of print] Review.

Development of a Pediatric Goal-Centered Upper Limb Spasticity Home Exercise Therapy Program for Use in a Phase-III Trial of Abobotulinumtoxina (Dysport(®)).

Shierk A, Jiménez-Moreno AC, Roberts H, Ackerman-Laufer S, Backer G, Bard-Pondarre R, Cekmece C, Pyrzanowska W, Vilain C, Delgado MR.

Phys Occup Ther Pediatr. 2018 Sep 11:1-12. doi: 10.1080/01942638.2018.1486346. [Epub ahead of print]

The Effect of Repeated Botulinum Toxin A Therapy Combined with Intensive Rehabilitation on Lower Limb Spasticity in Post-Stroke Patients.

Hara T, Abo M, Hara H, Sasaki N, Yamada N, Niimi M, Shimamoto Y.

Toxins (Basel). 2018 Aug 31;10(9). pii: E349. doi: 10.3390/toxins10090349.

Movement disorders phenomenology in focal motor seizures.

Fasano A, Di Bonaventura C, Bove F, Espay AJ, Morgante F, Fabbrini G, Munhoz RP, Andrade D, Borlot F, Bui E, Di Gennaro G, Iorio R, Katzberg H, Luigetti M, Striano P, Defazio G, Berardelli A.

Parkinsonism Relat Disord. 2018 Oct 16. pii: S1353-8020(18)30455-3. doi: 10.1016/j.parkreldis.2018.10.021. [Epub ahead of print]

Is deep brain stimulation therapy underutilized for movement disorders?

Shukla AW, Deeb W, Patel B, Ramirez-Zamora A.

Expert Rev Neurother. 2018 Oct 23. doi: 10.1080/14737175.2018.1538791. [Epub ahead of print] No abstract available.

Clinical Sleep-Wake Disorders I: Focus on Hypersomnias and Movement Disorders During Sleep.

Baumann CR.

Handb Exp Pharmacol. 2018 Oct 20. doi: 10.1007/164_2018_126. [Epub ahead of print]

Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease.

Bally JF, Méneret A, Roze E, Anderson M, Grabli D, Lang AE.

Mov Disord. 2018 Oct 19. doi: 10.1002/mds.27419. [Epub ahead of print]

Movement disorders associated with neuronal antibodies.

Dash D, Pandey S.

Acta Neurol Scand. 2018 Oct 18. doi: 10.1111/ane.13039. [Epub ahead of print] Review.

Movement disorders in emergency settings: a prospective study.

Dallocchio C, Matinella A, Arbasino C, Arno' N, Glorioso M, Sciarretta M, Braga M, Tinazzi M.

Neurol Sci. 2018 Oct 15. doi: 10.1007/s10072-018-3601-1. [Epub ahead of print]

Ultrasound elastography in neuromuscular and movement disorders.

Harmon B, Wells M, Park D, Gao J.

Clin Imaging. 2018 Oct 6;53:35-42. doi: 10.1016/j.clinimag.2018.10.008. [Epub ahead of print] Review.

Gray matter differences in patients with functional movement disorders.

Maurer CW, LaFaver K, Limachia GS, Capitan G, Ameli R, Sinclair S, Epstein SA, Hallett M, Horovitz SG.

Neurology. 2018 Oct 10. pii: 10.1212/WNL.0000000000006514. doi: 10.1212/WNL.0000000000006514. [Epub ahead of print]

Genetic landscape of pediatric movement disorders and management implications.

Cordeiro D, Bullivant G, Siriwardena K, Evans A, Kobayashi J, Cohn RD, Mercimek-Andrews S.

Neurol Genet. 2018 Sep 26;4(5):e265. doi: 10.1212/NXG.0000000000000265. eCollection 2018 Oct.

Abstracts of the 2018 International Congress of Parkinson's Disease and Movement Disorders(®).

[No authors listed]

Mov Disord. 2018 Oct;33 Suppl 2:S1-S929. doi: 10.1002/mds.116. No abstract available.

Extensive exploration of a novel rat model of Parkinson's disease using partial 6-hydroxydopamine lesion of dopaminergic neurons suggests new therapeutic approaches.

Vetel S, Sérrière S, Vercouillie J, Vergote J, Chicheri G, Deloye JB, Dollé F, Bodard S, Tronel C, Nadal-Desbarats L, Lefèvre A, Emond P, Chalon S.

Synapse. 2018 Oct 28. doi: 10.1002/syn.22077. [Epub ahead of print]